Caris Life Sciences reported second quarter 2026 financial results on August 5, 2026. Total revenue increased 45% to $263.7 million, driven by a 55% rise in molecular profiling services revenue to $252.3 million and approximately 59,200 clinical cases. The company achieved a gross margin of 68%, reported a net loss of $0.6 million, and generated positive Adjusted EBITDA of $55.7 million. Management raised full-year 2026 revenue guidance to $1.03–$1.04 billion, reflecting expected growth of 27% to 28%. Additionally, the company announced a share repurchase program with approximately $82.1 million remaining under existing authorization and launched Caris Detect, a multi-cancer early detection blood test. Caris Life Sciences operates in the precision medicine and molecular diagnostics industry, developing genomic testing solutions for oncology.